Abstract
Introduction Little is known about when youth living with HIV (YLHIV) are most susceptible to disengagement from HIV care. The longitudinal HIV care continuum is an underutilized tool that can provide a holistic understanding of population-level HIV care trajectories and be used to compare treatment outcomes across groups. We aimed to explore effects of the Universal Test and Treat policy (UTT) on longitudinal care outcomes among South African youth living with HIV (YLHIV) and identify temporally precise opportunities for re-engaging this priority population.
Methods Using medical record and census data, we conducted a retrospective cohort study among youth aged 18-24 newly diagnosed with HIV between August 2015 and December 2018 in nine health care facilities in rural South Africa. We used weighted Fine and Grey sub-distribution proportional hazards models to characterize longitudinal care continuum outcomes in the population overall and stratified by treatment era of diagnosis. We estimated the proportion of individuals in each stage of the continuum over time and the mean time spent in each stage in the first year following diagnosis. Estimates for the two groups were compared using differences (diagnosis pre-UTT=referent).
Results A total of 420 YLHIV were included. By the end of the first year following diagnosis, just 23% of individuals had no 90-or-more-day lapse in care and were virally suppressed. Those diagnosed in the UTT era spent less time as ART-naïve (mean difference=-19.3 days; 95% CI: - 27.7, -10.9) and more time virally suppressed (mean difference=17.7; 95% CI: 1.0, 34.4) compared to those diagnosed pre-UTT adoption. Most individuals who were diagnosed in the UTT era and experienced a 90-or-more-day lapse in care disengaged between diagnosis and linkage to care or ART initiation and viral suppression.
Conclusions Implementation of UTT yielded modest improvements in time spent on ART and virally suppressed among South African YLHIV. However, meeting UNAIDS’ 95-95-95 targets remains a challenge in this priority population. Retention in care and re-engagement interventions that can be implemented between diagnosis and linkage to care (e.g., longitudinal counseling following diagnosis) or ART initiation and viral suppression may be particularly important to improving treatment outcomes among South African YLHIV.
Competing Interest Statement
Author LMF was supported in part by ViiV Healthcare, NIH Research Training Grant # D43 TW009340 funded by the Fogarty International Center, NINDS, NIMH, and NHBLI, and NIMHD grant T37 MD014218; author JKE was supported in part by NIH award # K01AI125087 funded by NIAID; additional funding for this project was provided in part by the American people through the President's Emergency Plan for AIDS Relief (PEPFAR) and United States Agency for International Development (USAID) under the Cooperative Agreement Project SOAR (Supporting Operational AIDS Research), # AID-OAA-14-00060 and the Department of Science and Innovation, the University of the Witwatersrand, and the Medical Research Council, South Africa. The content of this publication is the sole responsibility of the authors and does not necessarily reflect the views or policies of the U.S. Agency for International Development, PEPFAR, or the National Institutes of Health, and does not imply endorsement by the U.S. Government. The authors declare that they have no other competing interests.
Funding Statement
Author LMF was supported in part by ViiV Healthcare, NIH Research Training Grant # D43 TW009340 funded by the Fogarty International Center, NINDS, NIMH, and NHBLI, and NIMHD grant T37 MD014218; author JKE was supported in part by NIH award # K01AI125087 funded by NIAID; additional funding for this project was provided in part by the American people through the President's Emergency Plan for AIDS Relief (PEPFAR) and United States Agency for International Development (USAID) under the Cooperative Agreement Project SOAR (Supporting Operational AIDS Research), # AID-OAA-14-00060 and the Department of Science and Innovation, the University of the Witwatersrand, and the Medical Research Council, South Africa. The content of this publication is the sole responsibility of the authors and does not necessarily reflect the views or policies of the U.S. Agency for International Development, PEPFAR, or the National Institutes of Health, and does not imply endorsement by the U.S. Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of North Carolina at Chapel Hill's Institutional Review Board, the University of the Witwatersrand's Human Research Ethics Committee, and the Mpumalanga Provincial Health Research Committee. All individuals provided written informed consent or assent for inclusion of their electronic health records in the Agincourt-HDSS Clinic Link System.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of authors: LMF: flindsey{at}wustl.edu
JKE: jessedwards{at}unc.edu
NM: Nkosinathi.masilela{at}wits.ac.za
FXG-O: f.gomez-olivecasas{at}wits.ac.za
NH: nhaberland{at}popcouncil.org
BWP: bpence{at}unc.edu
JM: jmaselko{at}unc.edu
KM: kmuessig{at}med.unc.edu
CWK: chodziwadziwa.kabudula{at}wits.ac.za
MKD: mi-suk{at}berkeley.edu
SAL: sheri.lippman{at}ucsf.edu
KK: Kathleen.kahn{at}wits.ac.za
AP: apettif{at}email.unc.edu
Data Availability
The datasets analyzed during the current study are not publicly available due to the sensitive nature of HIV treatment and care data. Data may be made available from the study team upon reasonable request.
Abbreviations
- ART
- anti-retroviral therapy
- HDSS
- Health and Socio-Demographic Surveillance System study area
- HIV
- human-immunodeficiency virus
- LTFU
- lost-to follow-up
- UNAIDS
- United Nations’ Joint Programme on HIV/AIDS
- UTT
- Universal Test and Treat policy
- YLHIV
- youth living with HIV